{"name":"Galmed Research and Development, Ltd.","slug":"galmed-research-and-development-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOV2RXUmsxUHJhNWNLMFRJOER5eE5kT1ljSDliX2tzNHZ6MmRqazdLdVUzRDZMWWpUNE1pS2dxM2lZUEtjeW5XQTkzdmtLcVdpYW9qTmJlQVR1cV84enBvazV6ZjJNTDVRVGVBbUlNcVdYZ2hPXzhnS0FPM1BEem9pZlU2ckRjVkJKSEV0ZXZDbUk4MjZ2YlVJ?oc=5","date":"2026-04-06","type":"trial","source":"openPR.com","summary":"Liver Fibrosis Clinical Trial Pipeline Accelerates as 50+ - openPR.com","headline":"Liver Fibrosis Clinical Trial Pipeline Accelerates as 50+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE8taER2Z1JSWHNmb0JvMjRwUHBVblFiaUFIWlpWZjgzUG4yTWNUYy1TaThGSkVVYTN1YW8yRGRoWVVZS2Y4ZmhiQVJiVGc5V3hJS0RmN3hzbFJFdW5RbEJF?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"GLMD Stock Price, Quote & Chart | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill","headline":"GLMD Stock Price, Quote & Chart | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNeWdyWDI1WlEzOGlVZEI5WnJiMGVQOHVwVnNkRUtsRDZXOGpjcDdqV09KMHpxa3dwOUhvUEFra3RrVzllQUtRdi03NWNtSWZ3RmR6Z2g3R1VQNTNOMWxQSVUxaGJ0WXR5Nk16OC1jSWRhc3FMSGhIMHd5N1ZjUkZoVE0xdnU2Y2NfeFV0dlRmQ09kZnBKbHlXN3k2a1NJdmI3Qkh6Q3d1eUVtNFhQY05vbkNFaDk4WlNOTzNHR1gzOFg5bThoak1zM0J1WnEyYnJyeVU4ei1xOEpDYTlHMHdyNHJVaHRjY2pEbXpfTWRQbkpnSUU?oc=5","date":"2026-03-31","type":"earnings","source":"PR Newswire","summary":"Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - PR Newswire","headline":"Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPWldoQ2Exc1BMclFSWFQtRVBPb0Rtd0xqWGxXdVF4RUlBZW5hZGVMUU5fQmtSbk9uRjBMWUV3OUJmTGxVZUt5UF9hVjZBRHBjUXBXdWVIV2x4X3ZtX2cwdE9DdWV3NXhrUHRibV9mamVUY3loZndFY1YwZEdKazZmWWxJWFlERl9qWUg5UmlxMVBxOEZNbG9zeVJvb1o4VjBiMndXOXI1eDBjamhJUS1scVEyWDNzN2VOYVdEUUJEaEZuVzBpeGpZ?oc=5","date":"2026-03-31","type":"pipeline","source":"Stock Titan","summary":"Going concern doubts and funding limits in Galmed (NASDAQ: GLMD) 2025 20-F - Stock Titan","headline":"Going concern doubts and funding limits in Galmed (NASDAQ: GLMD) 2025 20-F","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPZl9HYldTd3RsTENHejVyUjFibjVpM3ZxNVhXemx3NEtwT1U3S1lLQk1tT0Z3RldtNGVlMlBfTnFSN3QybGUzenFDVDZBS2xMYXdpSGt6U1FnSkhtUlEtdHhXdTFfaE1QQzRlWHJqdmU1MWNXY2VJUmdoQUtib014TklBcTFuczduNDRQMnRiM3BaS0RLcTJmU3JLU1FMZ0pSRDJ3WFBUeVdIUzk0cjlpZS1XSnY2SThHbEdJcTRGdw?oc=5","date":"2026-03-31","type":"pipeline","source":"Stock Titan","summary":"Galmed posts 2025 annual report online, offers free copies - Stock Titan","headline":"Galmed posts 2025 annual report online, offers free copies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOMk1uNkJ0ZGMzaDhaeGFhZlFnYUR4NnVPd3ZCRWVMSXpTUGQtTDVOQ0xLckpoVjg4eTZaMDRPeEFHcWVGeDhnVHIzUjRnOTB5cUpmRkN3TzQ5Yk4xa0VOa3lKU3FxQnhrdHNEb1Npd2hmeXdEbUpjaHh5UUNYSGE0UXFCalVUQk1lZGlpNElUZjZTdUxnSGY2WktmNC01R01yMTU3S0NkQ0lpbXBPNk0wbzFPWl9jRHk3bVhLSElWVWVJUUNXbndTOFlxaFl4OVYxWVRj?oc=5","date":"2026-01-30","type":"pipeline","source":"PR Newswire","summary":"Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PR Newswire","headline":"Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWmhiOHBwTUdsZ21wR3hSNFRjM1lNTlRVa1RCc1lmWDByZnFibkNBdk5FRUlOS0RCekJHV2tKaXFBM2VMRHdPZFM5UUJEaHBackJ6ejRoeEZnTTFtTmVET0Jlamk3SEtJekNNUXI2dHFkV0xGMDJGT2dtZ203MG12M2hNc0NxaFJTOVVtM3RWTFljQnB1OHh5ajcwYXI1NXVlSTdtd2JxaWtyV25uaFUxbXVQejRZNEdiVjdBMmxudWVXQWZCQ0lCMHNwbk9NSUk4bEtDckJpQjJEWGVENENUdFJrQVBkRVE?oc=5","date":"2025-12-08","type":"pipeline","source":"PR Newswire","summary":"Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PR Newswire","headline":"Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOZFk2dFJCY1JnTXU5SEVoWFNhVVgzTU9hNm12ZW1Wb1NERTBRZFFkX2ZZM2tWd2FfQXJwS3BNOUN1VkNUbEU0aU9CSG9MX0VSUHRQZldaQ0NEVEhlMURMc1VDWlNKZWlTRW9xX0tEanlkV1FUUUp3TjVNN05nUnp3MjltVm9XNjgtT3JDLXN0UC1palZPZXZqOUQ3MkNwMmhO?oc=5","date":"2025-12-01","type":"pipeline","source":"PR Newswire","summary":"Galmed Issues CEO Letter to Shareholders - PR Newswire","headline":"Galmed Issues CEO Letter to Shareholders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNTlk2cjYydVBSWm00MnV4alphUE5HRFplR0lDUkd4U1JNamExNHpsM2lyLTlSdFRjUkh2amdyWXUwdU5DZ19HNE16c2VvaG8tcVlIRkRfRGUtQ3oxTGZneFdyMmNFdkprc3dzMDgwNEZXM3hWTDBHZnJiWV8yUnFHbUNBRUpLQVQwTm5IT3g3dTdOQ21icmJSLV96ZHBGaEU1Nk5pRmlMcUxmeVJWWWhIVnpUaTZIQ2JjTmZ4Rw?oc=5","date":"2025-11-18","type":"pipeline","source":"Stock Titan","summary":"Galmed (NASDAQ: GLMD) AM-001 shows 5-fold, 3-fold Aramchol bioavailability improvement - Stock Titan","headline":"Galmed (NASDAQ: GLMD) AM-001 shows 5-fold, 3-fold Aramchol bioavailability improvement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxNdTViQ1VoUDgwZ3dZbXRiMzhxZUpxSmg2VV9TV0FxZEo0dE5YVUN2R0ItRVA5cW03ekdHM0hIQTFwZHFtbU9Ta0txMS1yUDlTUDZPZy1qU3JBa2RDcDdoT1dEZzdCOHRhOWRsZlBHbVdlT0g4anMtRklyUHZ2R0hrNnFYNmZFYWlPRHlpdnJkRkZkRUp1cV9udGhvei1tdGpLNjVGTTZCUVdjSGNzMVEzLXdKZUlZWlhBWmFUcDdpQUJPeEFjWkpaTjFnVm1Db0lVNU9NUDdhN2s4OGtQVFdyWk5LZFJPdWFzc1o4eFZiTFozQ3FDSVVKMi1CZGZTRkx5Z1dPQndoVmVBdnplNFk0T1VBRjZjdHBPZG4xUFNNbTc5MVREcmRnWE5TdldxUVExdlFIOUV4UnY0czlfNHZRNnFoajcxWEdQTl9kY01PZ09sb3ZESFNN?oc=5","date":"2025-11-17","type":"pipeline","source":"PR Newswire","summary":"Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro - PR Newswire","headline":"Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Sig","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5nTkVYWnN1WTZYcVZqVTJ6RENrUTJGRklqWTZEbGJfZmZJVGJKdDRpUXlYV3ZLWk1kYkxVMG1hWktoLTlhYkZLRERqd3UtRWpiUjFr?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"GLMD Stock Price, News & Analysis - Stock Titan","headline":"GLMD Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPTk9oMmJOUXdLSUVIVEoyYUxGbDIwbFl1X296dWxBWExRZVl3SWNiVDllRC1wLTJKSVczeXBKSXQ0V3JZMzNrak1xYjNubF90WGlidWVCNkdObXZ2OTlpdGdnblZRSUw1NERNOGZ0Z1hxT08yVTdzUXJVSmlGZ1gtM05KeXlpZmExRlNLZHJaQnluVGNKemdSV2p4NTJzWFczSE0tWDNnT0JyVXQtZU1zSEU5cTdVZnVfOGQzd2Y1QW42MjVlQU9oTzNHdi1kTThnRkswcHlaX3dSVmdNOWZnbTI5dzlUYk1aQTVhbU85NzBTQVFyX1B4bUdR?oc=5","date":"2025-04-15","type":"pipeline","source":"PR Newswire","summary":"Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - PR Newswire","headline":"Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}